Compare ZVIA & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | PLYX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 112.7M |
| IPO Year | 2021 | 2025 |
| Metric | ZVIA | PLYX |
|---|---|---|
| Price | $1.22 | $1.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $3.96 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 362.9K | 22.2K |
| Earning Date | 11-04-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.88 | ★ 77.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | N/A |
| Revenue This Year | $8.02 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $1.85 |
| 52 Week High | $2.78 | $9.18 |
| Indicator | ZVIA | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 46.50 |
| Support Level | $1.13 | $2.03 |
| Resistance Level | $1.50 | $2.21 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 9.23 | 34.89 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.